There is a lack of studies that rigorously and systematically assess the economic burden of cardiovascular diseases (CVDs) related to the use of antiretroviral therapy (ART). We aimed to assess the association between adherence to ART and economic burden of CVDs in an HIV-infected population.
Methods
Taiwan's National Health Insurance Research Database 2000–2011 was utilized for analyzing 18,071 HIV-infected patients free of CVDs before HIV diagnosis. The level of adherence to ART was measured by the medication possession ratio (MPR). Generalized estimating equations analysis was applied to estimate the cost impact of a variety of CVDs. All costs were presented in 2018 US dollars.
Results
The incidence of CVDs ranged from 0.17/1000 person-years (cardiogenic shock) to 2.60/1000 person-years (ischemic heart diseases (IHDs)). The mean annual medical cost for a base-case patient without CVDs was US$3000. Having cerebrovascular diseases, myocardial infarction, heart failure, arrhythmia, and IHDs increased annual costs by 41%, 33%, 30%, 16%, and 14%, respectively. The cost impact of incident CVDs in years with high adherence to ART (MPR ≥ 0.8) was significantly lower than that in years with low adherence (MPR < 0.1) (e.g. having cerebrovascular diseases in the high- versus low-adherence years increased annual costs by 21% versus 259%, respectively).
Conclusion
The economic burden of incident CVDs in an HIV-infected population was compelling and varied by the extent of using ART. A reduced economic impact of CVDs was found in years when patients possessed a greater adherence to ART.
FeinsteinMJBahiruEAchenbachC, et al.Patterns of Cardiovascular mortality for HIV-infected adults in the United States: 1999 to 2013. Am J Cardiol2016; 117: 214–220.
2.
FreibergMSChangCCKullerLH, et al.HIV infection and the risk of acute myocardial infarction. JAMA Intern Med2013; 173: 614–622.
3.
MarcusJLLeydenWAChaoCR, et al.HIV infection and incidence of ischemic stroke. AIDS2014; 28: 1911–1919.
4.
ButtAAChangCCKullerL, et al.Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med2011; 171: 737–743.
5.
FreibergMSMcGinnisKAKraemerK, et al.The association between alcohol consumption and prevalent cardiovascular diseases among HIV-infected and HIV-uninfected men. J Acquir Immune Defic Syndr2010; 53: 247–253.
6.
DeeksSG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med2011; 62: 141–155.
7.
KaplanRCSinclairELandayAL, et al.T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis2011; 217: 207–213.
8.
GrinspoonSCarrA. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med2005; 352: 48–62.
9.
Friis-MollerNSabinCAWeberR, et al.Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med2003; 349: 1993–2003.
10.
LadapoJARichardsAKDeWittCM, et al.Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: a cross-sectional study. J Am Heart Assoc2017; 6: e007107.
11.
BurkholderGATamhaneARSalinasJL, et al.Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients. Clin Infect Dis2012; 55: 1550–1557.
12.
CarrASamarasKThorisdottirA, et al.Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet1999; 353: 2093–2099.
13.
Strategies for Management of Antiretroviral Therapy Study GroupEl-SadrWMLundgrenJ, et al.CD4 + count-guided interruption of antiretroviral treatment. N Engl J Med2006; 355: 2283–2296.
14.
ZicariSSessaLCotugnoN, et al.Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses2019; 11: 200.
15.
BezabheWMChalmersLBereznickiLR, et al.Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine (Baltimore)2016; 95: e3361.
16.
Insight Start Study GroupLundgrenJDBabikerAG, et al.Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med2015; 373: 795–807.
17.
OrtegoCHuedo-MedinaTBLlorcaJ, et al.Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. AIDS Behav2011; 15: 1381–1396.
18.
ShubberZMillsEJNachegaJB, et al.Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med2016; 13: e1002183.
19.
NeuhausJJacobsDRJrBakerJV, et al.Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis2010; 201: 1788–1795.
20.
BorgesAHSilverbergMJWentworthD, et al.Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS2013; 27: 1433–1441.
21.
BorgesAHO'ConnorJLPhillipsAN, et al.Interleukin 6 is a stronger predictor of clinical events than high-sensitivity c-reactive protein or d-dimer during HIV infection. J Infect Dis2016; 214: 408–416.
22.
FeinsteinMJHsuePYBenjaminLA, et al.Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation2019; 140: e98–e124.
23.
HernándezSVidalMPedrolE. Evaluación del riesgo cardiovascular e intervención en los pacientes con VIH. Enfermedades Infecciosas y Microbiología Clínica2009; 27: 40–47.
24.
PirroMFrancisciDBianconiV, et al.NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: the NU-TRY (HIV) randomized cross-over trial. Atherosclerosis2019; 280: 51–57.
25.
ShahASVStelzleDLeeKK, et al.Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation2018; 138: 1100–1112.
26.
LamWYFrescoP. Medication adherence measures: an overview. BioMed Res Int2015; 2015: 217047.
27.
SandersGDNeumannPJBasuA, et al.Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA2016; 316: 1093–1103.
28.
BaraiNMonroeALeskoC, et al.the association between changes in alcohol use and changes in antiretroviral therapy adherence and viral suppression among women living with HIV. AIDS Behav2017; 21: 1836–1845.
29.
MessouEChaixMLGabillardD, et al.Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Cote d'Ivoire. J Acquir Immune Defic Syndr2011; 56: 356–364.
30.
MessouEKouakouMGabillardD, et al.Medication possession ratio: predicting and decreasing loss to follow-up in antiretroviral treatment programs in Cote d'Ivoire. J Acquir Immune Defic Syndr2011; 57(Suppl 1): S34–S39.
31.
BallingerGA. Using generalized estimating equations for longitudinal data analysis. Organ Res Methods2004; 7: 127–150.
32.
WangM. Generalized estimating equations in longitudinal data analysis: a review and recent developments. Adv Stat2014; 2014: 1–11.
33.
KahmKLaxyMSchneiderU, et al.Health care costs associated with incident complications in patients with type 2 diabetes in Germany. Diabetes Care2018; 41: 971–978.
34.
ChenJLiuLShihYC, et al.A flexible model for correlated medical costs, with application to medical expenditure panel survey data. Stat Med2016; 35: 883–894.
35.
NordellADMcKennaMBorgesAH, et al.Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc2014; 3: e000844.
36.
HemkensLGBucherHC. HIV infection and cardiovascular disease. Eur Heart J2014; 35: 1373–1381.
37.
PaulaAAFalcaoMCPachecoAG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther2013; 10: 32.
38.
GardnerEMMaraviMERietmeijerC, et al.The association of adherence to antiretroviral therapy with healthcare utilization and costs for medical care. Appl Health Econ Health Policy2008; 6: 145–155.
39.
ChengCLKaoYHYLinSJ, et al.Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf2011; 20: 236–242.
40.
ChengC-LLeeC-HChenP-S, et al.Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan. J Epidemiol2014; 24: 500–507.
41.
McCormickNBholeVLacailleD, et al.Validity of diagnostic codes for acute stroke in administrative databases: a systematic review. PLoS One2015; 10: e0135834.
42.
LinC-CLaiM-SSyuC-Y, et al.Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc2005; 104: 157–163.
43.
WuC-SLaiM-SGauSS-F, et al.Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. PloS One2014; 9: e112257.
44.
Centers for Disease Control, R.O.C. (Taiwan). HIV/AIDS case report 2016. R.O.C. (Republic of China), Taiwan: Centers for Disease Control.
45.
Marks KingRVidrineDJDanyshHE, et al.Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers. AIDS Patient Care STDs2012; 26: 479–485.
46.
O'CleirighCValentineSEPinkstonM, et al.The unique challenges facing HIV-positive patients who smoke cigarettes: HIV viremia, ART adherence, engagement in HIV care, and concurrent substance use. AIDS Behav2015; 19: 178–185.
47.
ShuterJBernsteinSL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res2008; 10: 731–736.
48.
WebbMSVanablePACareyMP, et al.Medication adherence in HIV-infected smokers: the mediating role of depressive symptoms. AIDS Educ Prev2009; 21: 94–105.
49.
LichtensteinKAArmonCBuchaczK, et al.Low CD4 + T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis2010; 51: 435–447.
50.
TohHSYangCTYangKL, et al.Reduced economic burden of AIDS-defining illnesses associated with adherence to antiretroviral therapy. Int J Infect Dis2019; 91: 44–49.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
